Dupilumab High-Dose Effects

## Adverse Effects of High-Dose Dupilumab Based on the retrieved evidence, there is **no specific safety data or dedicated analysis for "high-dose" dupilumab** across the available sources. The adverse event profiles described in the retrieved literature and drug labels are derived from **standard approved dosing regimens** across various indications (atopic dermatitis, asthma, CRSwNP, COPD, EoE, prurigo nodularis, etc.). The available evidence consistently demonstrates that dupilumab is **generally well-tolerated**, with adverse event rates comparable to placebo across multiple indications [1][2][8][10]. The safety profile does not appear to differ substantially by dose level in the retrieved data, though no dedicated high-dose safety analysis is provided. ### Common Adverse Events (≥2-5% incidence across indications) | Adverse Event | Indications Reported | Incidence Range | |---------------|---------------------|-----------------| | **Injection site reactions** | All indications (AD, asthma, CRSwNP, EoE, PN, CSU, BP) | Most common AE across all studies [1][3][5][6] | | **Nasopharyngitis** | COPD, CRSwNP, PN | 9-12% [2][3][8] | | **Headache** | COPD, CRSwNP, asthma | 6-8% [2][3][8] | | **Upper respiratory tract infection** | COPD, EoE, pediatric asthma | 6-12% [3][8][10] | | **Arthralgia** | EoE, COPD, PN, BP | ≥2% [3][6] | | **Diarrhea** | COPD, PN | 3-5% [3][8] | | **Back pain** | COPD | 3-5% [3][8] | | **Conjunctivitis** | AD, CRSwNP, PN, BP | Higher in atopic background patients [1][4][5][7] | | **Eosinophilia** | AD, asthma, COPD, pediatric asthma | 0.7-5.9% (mostly self-limited) [3][10] | | **Hypertension** | COPD | 3.6-6.0% [8] | ### Clinically Important Safety Considerations **Conjunctivitis/Ocular Effects**: - More prevalent in patients with atopic background [1][4] - Risk factors: prior history of conjunctivitis, more severe AD before treatment [7] - Management: baseline ophthalmology exam, lubricant eye drops (artificial tears) twice daily at initiation [7] - Severe symptoms (blurred vision, decreased acuity, purulent discharge, photophobia, eye pain) require urgent ophthalmology evaluation [7] - May require topical corticosteroids or immunomodulatory eye drops (tacrolimus, cyclosporine, lifitegrast) [7] **Eosinophilia**: - Observed across multiple indications [3][10] - Most episodes are self-limited laboratory findings without clinical symptoms [10] - One reported case of symptomatic eosinophilia requiring hospitalization and permanent discontinuation in pediatric asthma trial [10] **Infections**: - No increased risk of serious infections overall [6] - Parasitic infections reported (2.6% in pediatric asthma trial), all mild and responsive to anthelmintic therapy [10] - Screening for TB, HIV, or hepatitis is **not required** before initiation [6] **Serious Adverse Events**: - Rates comparable to placebo across all indications [1][2][8] - Serious AE rates: 2-15.5% (dupilumab) vs 4-15.5% (placebo) depending on indication [2][8] - No increased risk of major adverse cardiovascular events (MACE) [8] - No deaths attributable to dupilumab in the retrieved trials [2][8][10] **Lymphoma Risk**: - A hypothesis has been raised regarding potential increased lymphoma risk in AD patients, but **causality remains questionable and unclarified** [4] ### Key Safety Advantages - Therapeutic drug monitoring is **not recommended** [6] - Clinically important immunogenicity has **not been reported** [6] - Antidrug antibody responses observed in 6.3% (dupilumab) vs 3.0% (placebo) in pediatric asthma trial, without apparent clinical impact [10] - Discontinuation rates due to AEs are low (1.8-3.0%) and comparable to placebo [8][10] ### Critical Gap The retrieved evidence does **not contain any dedicated safety analysis for high-dose dupilumab regimens**. All safety data presented are from standard approved dosing protocols. If "high-dose" refers to a specific clinical trial protocol or off-label dosing strategy, the safety profile for such regimens remains uncharacterized in the available literature. --- *This analysis is based on retrieved evidence from drug labels, clinical guidelines, and published trials. Clinical decisions should be made in consultation with the official prescribing information and individual patient assessment.*